On July 31, 2020, Mulas, Olga; Caocci, Giovanni; Stagno, Fabio; Bonifacio, Massimiliano; Annunziata, Mario; Luciano, Luigiana; Orlandi, Ester Maria; Abruzzese, Elisabetta; Sgherza, Nicola; Martino, Bruno; Albano, Francesco; Galimberti, Sara; Pregno, Patrizia; Bocchia, Monica; Castagnetti, Fausto; Tiribelli, Mario; Binotto, Gianni; Gozzini, Antonella; Capodanno, Isabella; Fozza, Claudio; Luzi, Debora; Efficace, Fabio; Simula, Maria Pina; Scaffidi, Luigi; De Gregorio, Fiorenza; Elena, Chiara; Trawinska, Malgorzata Monika; Cattaneo, Daniele; Attolico, Imma; Barate, Claudia; Pirillo, Francesca; Sicuranza, Anna; Gugliotta, Gabriele; Stella, Rossella; Scalzulli, Emilia; Iurlo, Alessandra; Foa, Robin; Breccia, Massimo; La Nasa, Giorgio published an article.Category: piperazines The title of the article was Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. And the article contained the following:
Hypertension is a commonly reported comorbidity in patients diagnosed with chronic myeloid leukemia (CML), and its management represents a challenge in patients treated with 2nd- or 3rd-generation tyrosine kinase inhibitors (TKIs), considering their addnl. cardiovascular (CV) toxicity. The renin angiotensin system (RAS) contributes to hypertension genesis and plays an important role in atherosclerosis development, proliferation, and differentiation of myeloid hematopoietic cells. We analyzed a cohort of 192 patients with hypertension at CML diagnosis, who were treated with 2nd- or 3rd-generation TKIs, and evaluated the efficacy of RAS inhibitors (angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-II receptor blockers (ARBs)) in the prevention of arterial occlusive events (AOEs), as compared with other drug classes. The 5-yr cumulative incidence of AOEs was 32.7 ± 4.2%. Patients with SCORE ≥ 5% (high-very-high) showed a significantly higher incidence of AOEs (33.7 ± 7.6% vs 13.6 ± 4.8%, p = 0.006). The AOE incidence was significantly lower in patients treated with RAS inhibitors (14.8 ± 4.2% vs 44 ± 1%, p < 0.001, HR = 0.283). The difference in the low and intermediate Sokal risk group was confirmed but not in the high-risk group, where a lower RAS expression has been reported. Our data suggest that RAS inhibitors may represent an optimal treatment in patients with hypertension and CML, treated with 2nd or 3rdG TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines
The Article related to anticancer ace inhibitor angiotensin receptor blocker thrombosis hypertension leukemia, arterial occlusive events, chronic myeloid leukemia, hypertension, renin angiotensin system inhibitors, tki and other aspects.Category: piperazines
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics